首页> 外文会议>International Polymers for Advanced Technologies conference >A High Content Screening Assay for Evaluation of Biomaterial-Mediated Cell Fusion Processes
【24h】

A High Content Screening Assay for Evaluation of Biomaterial-Mediated Cell Fusion Processes

机译:用于评价生物材料介导的细胞融合方法的高含量筛选测定

获取原文

摘要

Biomaterials are of increasing importance in regenerative medicine and entail delivery systems in somatic cell therapies, matrices for tissue engineering or tissue regeneration. The evaluation of biomaterial induced biological effects remains a key issue in clinical application. Cell-based assays for potential cytotoxic and immunological responses have been developed but are often inadequate to address cell-type specific responses to biomaterials. To quantitatively monitor attachment, survival, proliferation and fusion-controlled differentiation of osteoclasts (bone resorbing cells), a High Content Screening (HCS) assay has been developed based on osteoclast differentiation of the murine monocytic cell line RAW264.7. This assay was applied to investigate the influence of degradation products of polymers fromgelatin and lysine diisocyanate, which display tailorable mechanical properties and have potential as biomaterials. The data show that the degradation products inhibit formation of multinuclear osteoclasts and suggest a potential support of bone regeneration by suppression of bone resorption.
机译:生物材料在再生药物中具有越来越重要,并且在体细胞疗法中的递送系统,组织工程或组织再生的基质。对生物材料诱导的生物效应的评价仍然是临床应用中的关键问题。已经开发了基于细胞的测定,用于潜在的细胞毒性和免疫反应,但通常不充分,以解决对生物材料的细胞类型特异性反应。为了定量地监控连接,存活,增殖和破骨细胞(骨再吸收细胞)的融合控制分化,带有高含量筛选(HCS)测定已经基于鼠单核细胞系RAW264.7的破骨细胞分化的发展。该测定适用于研究的聚合物的降解产物的影响fromgelatin和赖氨酸二异氰酸,其显示调节的机械性能,并且具有用作生物材料的潜力。数据显示,降解产品抑制多核破骨细胞的形成,并通过抑制骨吸收来表明骨再生的潜在支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号